Loading clinical trials...
Loading clinical trials...
Phase II Study of Zanubrutinib in Combination With Rituximab and Methotrexate, Followed by Zanubrutinib Maintenance in Patients With Secondary Central Nervous System Lymphoma (SCNSL)
Conditions
Interventions
Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Locations
1
China
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
Start Date
February 26, 2021
Primary Completion Date
February 26, 2024
Completion Date
May 26, 2024
Last Updated
May 31, 2022
Lead Sponsor
Peking University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions